These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Synthesis and Initial Pharmacology of Heterobivalent Ligands Targeting Putative Complexes of Integrin αVβ3 and PAR2

revised on 22.09.2019, 01:39 and posted on 26.09.2019, 14:53 by Mark Majewski, Disha Gandhi, Trudy Holyst, Zhengli Wang, Irene Hernandez, Ricardo Rosas, Jr., Saravanan Subramaniam, Jieqing Zhu, Hartmut Weiler, Chris Dockendorff
Unpublished data from our labs led us to hypothesize that activated Protein C (aPC) may initiate an anti-inflammatory signal in endothelial cells by modulating both the integrin αVβ3 and Protease-Activated Receptor 2 (PAR2), which may exist in close proximity on the cellular surface. To test this hypothesis and to probe the possible inflammation-related pathway, we designed and synthesized heterobivalent ligands composed of modified versions of two αVβ3 ligands and two agonists of PAR2. These novel ligands were connected via copper-catalyzed alkyne-azide cycloadditions with polyethylene glycol (PEG) spacers of variable length. Initial in vitro pharmacology with EA.hy926 and HUVEC endothelial cells indicated that these bivalent ligands are effective binders of αVβ3 and potent agonists of PAR2. These bivalent ligands were also used in preliminary studies investigating their effects on PAR2 signaling in the presence of inflammatory agents, and represent the first examples of ligands targeting both PARs and integrins.


Novel Approaches to the Modulation of Protease-Activated Receptor (PAR) Signaling

National Heart Lung and Blood Institute

Find out more...

Clinical and Translational Science Institute of Southeast Wis-consin: 8UL1TR000055

Regulation of Innate Immunity by Coagulation Receptors

National Heart Lung and Blood Institute

Find out more...

Structural Transition of Cellular Integrins and Applications Thereof

National Heart Lung and Blood Institute

Find out more...


Email Address of Submitting Author


Marquette University


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest

Version Notes

Version 2 (uploaded 2019 09 21) contains corrections to the experimental details of Figure 5. A complete Supporting Info file is also attached.